<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800720</url>
  </required_header>
  <id_info>
    <org_study_id>NTU-MATFMS</org_study_id>
    <nct_id>NCT02800720</nct_id>
  </id_info>
  <brief_title>Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome</brief_title>
  <official_title>Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nottingham Trent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nottingham Trent University</source>
  <brief_summary>
    <textblock>
      A Randomised Controlled Trial to evaluate the effectiveness of a Second-Generation&#xD;
      Mindfulness-Based Intervention known as Meditation Awareness Training (MAT) for treating&#xD;
      fibromyalgia syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Fibromyalgia syndrome (FMS) is a chronic pain disorder that frequently leads to&#xD;
      poor quality of life. The need for more effective FMS treatments has prompted empirical&#xD;
      investigations into the applications of mindfulness for treating the condition. However,&#xD;
      studies have predominantly focused on first-generation mindfulness-based interventions&#xD;
      (FG-MBIs). To date, a randomised controlled trial (RCT) assessing the effectiveness of a&#xD;
      second-generation mindfulness-based intervention (SG-MBI) for treating FMS has not been&#xD;
      undertaken. SG-MBIs are distinct from FG-MBIs because they are overtly spiritual in nature&#xD;
      and employ (i) a greater range of (normally secularised) meditative/spiritual techniques,&#xD;
      (ii) ethics as a key component of the taught programme, and (iii) an instructor training&#xD;
      programme that typically requires several years of supervised mindfulness practice.&#xD;
&#xD;
      Aims: To evaluate the effectiveness of Meditation Awareness Training (MAT) - an SG-MBI - for&#xD;
      treating FMS.&#xD;
&#xD;
      Method: Adults with FMS will receive MAT or an active control intervention known as&#xD;
      Cognitive-Behavioural Therapy for Groups. Assessments will be performed at pre-intervention,&#xD;
      post-intervention, and follow-up phases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revised Fibromyalgia Impact Questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scale Reference: Bennett, Friend, Jones, Ward, Han &amp; Ross (2009)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form McGill Pain Questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scale Reference: Melzack (1987)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scale Reference: Buysse, Reynolds Monk, Berman, &amp; Kupfer (1989)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression Anxiety and Stress Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Scale Reference: Lovibond &amp; Lovibond (1995)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Fibromyalgia Syndrome</condition>
  <arm_group>
    <arm_group_label>Meditation Awareness Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target Intervention Arm:&#xD;
8-week meditation intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Behavioural Therapy for Groups</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator Arm:&#xD;
8-week CBT-based intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Meditation Awareness Training</intervention_name>
    <description>8 Week Meditation Intervention</description>
    <arm_group_label>Meditation Awareness Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy for Groups</intervention_name>
    <description>8 week intervention based on Cognitive Behavioral Theory</description>
    <arm_group_label>Cognitive Behavioural Therapy for Groups</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of fibromyalgia syndrome&#xD;
&#xD;
          -  Aged between 18 and 65 years&#xD;
&#xD;
          -  Able to read and write using the English language&#xD;
&#xD;
          -  Available to complete an eight-week intervention and six-month follow-up assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently undergoing formal psychotherapy&#xD;
&#xD;
          -  Changes in psychopharmacology type or dosage one-month prior to intervention&#xD;
&#xD;
          -  Currently practicing mindfulness or meditation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Van Gordon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham Trent University</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nottingham Trent University</investigator_affiliation>
    <investigator_full_name>William Van Gordon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia Syndromey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Embedded Qualitative Study</doc_type>
      <doc_url>http://link.springer.com/article/10.1007/s12671-015-0458-8</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

